Contact

Please use this form to send email to PR contact of this press release:
OBI Pharma annonce le début d’une étude de phase 1/2 sur OBI-992, un conjugué anticorps-médicament (CAM) dirigé contre TROP2 pour le traitement du cancer

TO:

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.
	SEND EMAIL